Sobi posts 90% revenue growth for 4th-qtr 2019

13 February 2020

Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) today announced its results for the fourth quarter and full-year 2019. Revenue growth for the full-year was 56% with sales of 14,248 million Swedish kronor ($1.48 billion). The company’s shares were up nearly 5% in early trading, but later eased back.

2019 adjusted earnings before interest, taxes and amortization (EBITA) were 6,145 million kronor, resulting in an adjusted EBITA margin of 43% for the full year. Earnings per share (EPS) were 11.29 kronor versus 8.97 kroner if fourth quarter 2018.

For the fourth quarter, total revenue came in at 4,890 million kronor, up a massive 90% compared with the like 2018 period (82% per cent at constant exchange rates). Adjusted EBITA was 2,380 million kronor, an increase of 160%. EPS was 4.62 kronor versus 2.20 kronor.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK